FRAMINGHAM (02/27/2004) - Pharmacopeia Inc. plans to separate its drug discovery and software businesses into two independent companies. Wholly owned subsidiary Pharmacopeia Drug Discovery will be spun off to stockholders, and is expected to apply for its own NASDAQ listing. Pharmacopeia, meanwhile, will officially change its name to Accelrys and focus on scientific software development. Mark J. Emkjer, president of Pharmacopeia's software unit, is expected to become president and CEO of Accelrys.
- Free Whitepaper! The 5 criteria to help you select the right analytics platform for your organization.
- Free Whitepaper! Learn how to create an analytics environment that is governed, scalable and self-serve.
- Free Whitepaper! Learn how IT is evolving from producer to enabler, and fostering collaboration around analytics.